Vertex announces program updates for type 1 diabetes portfolio

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced several updates on the company's type 1 diabetes (t1d) portfolio. vx-264 update vertex has completed enrollment and dosing in parts a and b of the phase 1/2 vx-264 (cells + device) study and the planned analysis at day 90 for part b. in part b of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunopro.
VRTX Ratings Summary
VRTX Quant Ranking